Xaluritamig by Amgen for Prostate Cancer: Likelihood of Approval

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer.

Black women weigh emerging risks of ‘creamy crack’ hair straighteners

Deanna Denham Hughes was stunned when she was diagnosed with ovarian cancer last year. She was only 32. She had no family history of cancer,

August 1, 2023

Exclusive: Vijay Pande hands a16z biotech leadership to Vineeta Agarwala, moves to AI role

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 10, 2024

Roche bets again on Ionis in Huntington’s, Alzheimer’s

Roche is again pairing up with its decadelong partner Ionis Pharmaceuticals, paying $60 million upfront for the exclusive rights to two RNA assets, the companies

September 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.